The FDA's Janet Wood­cock talks about some big changes she's push­ing for in drug de­vel­op­ment, and agency re­views

Janet Wood­cock is per­haps the most in­flu­en­tial reg­u­la­tor at the FDA. And when the head of CDER talks about the changes be­ing made at the agency when it comes to clin­i­cal tri­al de­signs, or the need to re­or­ga­nize for a spe­cif­ic dis­ease are­na, an as­sess­ment of the ex­pan­sion of gene ther­a­py or I/O, com­mon de­vel­op­ment mis­takes, and so on, you can be sure the in­dus­try pays at­ten­tion to every word.

So it was with some ea­ger­ness that I opened up Ge­of­frey Porges’ sum­ma­ry of their re­cent con­ver­sa­tion about the FDA. And I wasn’t dis­ap­point­ed. In a wide-rang­ing ex­change with the SVB Leerink an­a­lyst, Wood­cock dis­cussed the grow­ing im­por­tance of pa­tient-re­port­ed out­comes in clin­i­cal tri­als, a cam­paign un­der­way now to see if CROs would help spur more bas­ket stud­ies to com­pare drugs head-to-head, and much, much more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER